"Groups representing PBMs &amp; drugmakers ramped up spending on lobbying. Powerful interests were laser-focused on the possible inclusion of provisions that would've cracked down on PBMs, reformed drug patents, &amp; delayed scheduled Medicare physician payment cuts."

#SinglePayer NOW!